13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001687078
Total reported value
$1.6B
$1.6B
43 檔
10.3%
At the close of Q1 2025, MPM BioImpact LLC disclosed equity holdings valued at approximately $1.6B, spread across 43 reported holdings.
In Q1 2025, MPM BioImpact LLC displayed an active expansion posture, initiating 43 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including CGEM, MDGL, ZLAB) accounted for 10.3% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 9.95% | +2.42% | — | |
| 2 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 5.72% | — | — | |
| 3 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 5.18% | — | +4.21% | |
| 4 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.18% | -0.02% | +2.42% | |
| 5 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 3.90% | — | -1.62% | |
| 6 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 3.85% | — | +1.20% | |
| 7 | NTRA | Natera Inc | Stock-Healthcare | 3.82% | +0.09% | -2.23% | |
| 8 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.71% | +0.46% | +10.77% | |
| 9 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.64% | — | +2.42% | |
| 10 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.62% | — | +1.60% | |
| 11 | GH | Guardant Health Inc | Stock-Healthcare | 3.24% | — | -2.23% | |
| 12 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.12% | — | +156.12% | |
| 13 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 2.84% | — | — | |
| 14 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.76% | — | -1.46% | |
| 15 | JANX | Janux Therapeutics Inc | Stock-Other | 2.63% | — | +146.61% | |
| 16 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.48% | +2.89% | NEW | |
| 17 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.12% | -0.70% | +0.26% | |
| 18 | WVE | Wave Life Sciences Ltd. | Stock-Other | 2.10% | — | +1.37% | |
| 19 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.93% | +1.81% | +1.04% | |
| 20 | ALKS | Alkermes plc | Stock-Healthcare | 1.92% | — | — | |
| 21 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.89% | — | +0.61% | |
| 22 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.86% | — | +58.57% | |
| 23 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 1.79% | — | — | |
| 24 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 1.79% | — | +9.66% | |
| 25 | TWST | Twist Bioscience CORP | Stock-Other | 1.76% | — | -2.35% | |
| 26 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.75% | -2.64% | EXIT | |
| 27 | VERA | Vera Therapeutics Inc | Stock-Other | 1.72% | — | +61.26% | |
| 28 | REPL | Replimune Group Inc | Stock-Other | 1.65% | — | +3.90% | |
| 29 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 1.55% | — | +1.30% | |
| 30 | CNTX | Context Therapeutics Inc | Stock-Other | 1.55% | -2.12% | — | |
| 31 | MBX | Mbx Biosciences Inc | Stock-Other | 1.44% | — | — | |
| 32 | NUVB | Nuvation Bio Inc | Stock-Other | 1.41% | — | +11.72% | |
| 33 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.34% | -0.53% | — | |
| 34 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.21% | — | +3.89% | |
| 35 | SLDB | Solid Biosciences Inc | Stock-Other | 1.04% | — | — | |
| 36 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.03% | +0.95% | +1.19% | |
| 37 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.79% | -0.49% | +1.19% | |
| 38 | VERUEUR | Veru Inc | Stock-Other | 0.56% | — | +53.84% | |
| 39 | HOWL | Werewolf Therapeutics Inc | Stock-Other | 0.40% | -0.08% | +0.87% | |
| 40 | DSGN | Design Therapeutics Inc | Stock-Other | 0.37% | — | +0.61% | |
| 41 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.17% | — | -3.96% | |
| 42 | RPTX | Repare Therapeutics Inc | Stock-Other | 0.14% | — | -33.40% | |
| 43 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.06% | — | -60.47% |
According to official SEC Form 13F filings, MPM BioImpact LLC reported a total U.S. public equity portfolio value of $1.6B across 43 disclosed positions in Q1 2025.
During Q1 2025, MPM BioImpact LLC's top holdings by market value included CGEM (9.9%)、MDGL (5.7%)、ZLAB (5.2%). The largest single position, CGEM, represented 9.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CGEM
市值: $57.9M
In Q1 2025, MPM BioImpact LLC made 43 total portfolio adjustments, initiating 43 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.